The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study

Pediatric Blood and Cancer

Volumn 62, Issue 9, 2015, Pages 1592-1596

  Totadri, Sidharth ^a   Bansal, Deepak ^a   Bhatia, Prateek ^a   Attri, Savita V ^a   Trehan, Amita ^a   Marwaha, R K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Arthropathy; Chelation; Desferal; Exjade; India

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; DEFERASIROX; DEFERIPRONE; FERRITIN; PROTEIN; BENZOIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ARTHRALGIA; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; SEX RATIO; SIDE EFFECT; SINGLE DRUG DOSE; THALASSEMIA MAJOR; TREATMENT DURATION; VOMITING; ADVERSE EFFECTS; ARTHROPATHY; BETA-THALASSEMIA; BLOOD; BLOOD TRANSFUSION; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; GASTROINTESTINAL DISEASE; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; FERRITINS; GASTROINTESTINAL DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; JOINT DISEASES; MALE; PROSPECTIVE STUDIES; PROTEINURIA; PYRIDONES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84938099189     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25533     Document Type: Article

References (18)

1. Kwiatkowski JL. Management of transfusional iron overload-Differential properties and efficacy of iron chelating agents. J Blood Med 2011; 2:135-149.
2. Fernandes JL. Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion (Paris) 2012; 52:2256-2268.
3. Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin 2009; 33:S58.
4. Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, Wood JC, Coates T. Combining two orally active iron chelators for thalassemia. Ann Hematol 2010; 89:1177-1178.
5. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol 2010; 85:460-461.
6. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis 2011; 47:33-40.
7. Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol 2011; 154:654-656.
8. Elalfy M, Adly AM, Wali Y, Tony S, Samir A, Elhenawy Y. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferipronre in severely iron-overloaded young beta thalassemia major patients. Eur J Haematol 2015;doi: 10.1111/ejh.12507
9. Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol 2013; 130:64-73.
10. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95:557-566.
11. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455-3462.
12. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583-1587.
13. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefàno I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118:330-336.
14. Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian J Pediatr 2004; 71:213-216.
15. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91:1343-1351.
16. Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol 2013; 88:251-260.
17. Marwaha RK, Bansal D, Sharma S, Kumar S, Trehan A, Duseja A, Chawla YK. Seroprevalence of hepatitis C and B virus in multiply transfused beta-thalassemics: Results from a thalassemic day care unit in north India. Vox Sang 2003; 85:119-120.
18. Taher AT, Musallam KM, Inati A. Iron overload: Consequences, assessment, and monitoring. Hemoglobin 2009; 33:S46-S57.